A First in Human Study of IBC-Ab002 in Persons With Early Alzheimer's Disease (AD)

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 23, 2023

Primary Completion Date

November 1, 2025

Study Completion Date

November 1, 2025

Conditions
Alzheimer's Disease
Interventions
BIOLOGICAL

IBC-Ab002

An anti-PD-L1 monoclonal antibody

OTHER

Placebo

Normal Saline

Trial Locations (10)

Unknown

Barzilai Medical Center, Ashkelon

Rabin Medical Center, Petah Tikva

Sheba Medical Center, Ramat Gan

Tel-Aviv Sourasky Medical Center, Tel Aviv

Brain Research Center, Amsterdam

University Hospital Southampton NHS Foundation Trust, Southampton

Dementia Research Centre, National Hospital for Neurology and Neurosurgery, London

Sheffield teaching Hospitals NHS Trust, London

BA1 3NG

RICE - Research Institute for the Care of Older People, Bath

SE5 8AF

King's College London - Institute of Psychiatry, Psychology & Neuroscience (IoPPN), London

Sponsors
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

Alzheimer's Association

OTHER

lead

Immunobrain Checkpoint

INDUSTRY